New study reveals how Atogepant prevents migraines and reduces rebound headaches in chronic sufferers, offering hope for ...

Although the new recommendation means people with migraine may get quicker access to the new generation of medications, it doesn’t mean throwing the proverbial baby out with the bathwater.

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

Migraine is the most common neurological condition in the world, with more than one in seven people suffering from migraines ...

The effectiveness of new migraine treatments has been compared to paracetamol in a new study, which suggests drugs developed in the 1990s should be more widely promoted to patients with the ...

Anti-CGRP antibodies vs onabotulinumtoxinA is not associated with increased cardiovascular disease risk in older patients ...

and there was a "high unmet need for treatment options". Robert Music, chief executive of The Migraine Trust, said the decision "brings new hope" by reducing the pain and length of a migraine attack.

This new evidence review was funded by AbbVie, the maker of Qulipta. Qulipta and other CGRP-blocking drugs tend to be much more expensive than older migraine drugs, according to the Association of ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

In conversation with Dr Peter Goadsby, Director of NIHR Clinical Research Facility and Professor of Neurology at King's ...

If you experience migraine, whether chronic or episodic ... an associate professor of neurology at Weill Cornell Medicine in New York City. “In most people, I don’t see nerve stimulation ...

Explore the complex relationship between migraines and weather conditions like barometric pressure, sunlight and temperature, ...